Landmark CRISPR Trial Marks First Ever Gene Editing Inside Human Body
By Ruchi Jhonsa, Ph.D. CRISPR editing is in the news again. But this time it is not for treating cancer. Instead, it is for repairing a mutated gene that causes …
Read MoreThe Next Generation Biotech Media
By Ruchi Jhonsa, Ph.D. CRISPR editing is in the news again. But this time it is not for treating cancer. Instead, it is for repairing a mutated gene that causes …
Read MoreBy Ruchi Jhonsa, Ph.D. Ornithine transcarbamylase (OTC) deficiency is an X linked, rare genetic disorder that is caused by a complete or partial lack of enzyme ornithine transcarbamylase. Resulting in …
Read MoreBy Ruchi Jhonsa, Ph.D. UPenn researchers report encouraging data from the first US trial that evaluated CRISPR editing in cancer patients Genome editing is increasingly becoming an attractive option for …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. After increasing the number of shares originally offered from 6.3 million to 10.6 million, Beam Therapeutics has raised $180 million in its initial public offering. …
Read MoreBy Ruchi Jhonsa, Ph.D. The San Francisco based startup, Mammoth Biosciences, co-founded by one of the pioneers of the CRISPR technology, Prof. Jennifer Doudna, raised $45 million in Series B funding …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. The Disease Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder predominantly affecting male children. This debilitating, muscle-weakening disease is the most common and severe form of muscular dystrophy. It …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Prof. Jennifer Doudna and Prof. Emmanuelle Charpentier bag the prestigious award for their pioneering work in developing the CRISPR/Cas9 editing technology. The Wolf Prize is an international …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. As 2019 comes to a close, we look back to some of the major scientific breakthroughs and headlines that lit up the year. From several …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Broad Institute researchers under the leadership of CRISPR pioneer Feng Zhang is entering a scientific collaboration with the Seattle-based biotech software company, for developing a safer gene-editing …
Read MoreBy Ruchi Jhonsa, Ph.D. Modifying the genome for correcting disease-causing genetic mutations or making designed babies seemed like a far-fetched idea a decade ago. But with technology like CRISPR, it …
Read More